LENZ Therapeutics Cuts Headcount ~75%, CEO to Step Down Dec. 1

What happened

LENZ Therapeutics, Inc., a Nasdaq-listed biopharmaceutical company based in Solana Beach, California, disclosed in a Form 8-K filed October 28, 2026 that its board approved a strategic reorganization that includes reducing headcount by approximately 75%, to approximately 40 full-time employees.

The company said the reorganization is intended to prioritize consumer marketing, allocate capital to maximize sales growth, and reduce operating expenses. It estimated it will incur non-recurring charges of approximately $5 million, primarily severance and related termination benefits, substantially all in the fourth quarter of 2026, when it expects the reorganization to be substantially completed.

Separately, the company announced that President and CEO Evert Schimmelpennink will leave those roles effective December 1, 2026, and resign from the board the same day. Chief Financial Officer Daniel Chevallard will become Interim President and CEO and principal executive officer while continuing as CFO and principal financial and accounting officer. The board will shrink to five members effective December 1.

The filing states that Schimmelpennink's decision to resign was not the result of any dispute or disagreement with the company on operations, policies, or practices.

The same day, the company reported financial results for the quarter ended September 30, 2026 in a press release attached as an exhibit to the filing. The filing itself does not state why the reorganization or the CEO transition is taking place beyond the stated goals of prioritizing consumer marketing, maximizing sales growth and reducing operating expenses.

The departure terms

Under a separation agreement dated October 28, 2026, Schimmelpennink stays on as President and CEO through December 1 and then serves as Strategic Advisor to the CEO through December 31, 2026. During that transition period he keeps his $731,400 annual base salary, participates in benefit plans, and his outstanding equity awards continue to vest.

Subject to conditions including a release of claims, he will receive a lump-sum cash payment of $731,400, equal to 12 months of base salary; a lump-sum payment of $309,016.50 for his 2026 bonus, calculated as his 65%-of-salary target multiplied by 65%, the company's estimate of 2026 goal achievement; and up to 12 months of COBRA health premium payments.

Vesting of his equity awards stops on December 31, 2026, and unvested portions are forfeited; the agreement provides no accelerated vesting. The exercise period for options vested as of that date is extended to the earlier of September 30, 2027 or the option's original expiration. The filing says he will not receive severance under the company's Executive Change in Control and Severance Policy.

Chevallard's interim letter sets his base salary at $650,000, replacing his CFO salary, and raises his target annual bonus from 45% to 60% of base salary. On October 30, 2026 he is to receive an option grant with an aggregate grant date fair value of about $1.5 million, at an exercise price equal to that day's closing price, in lieu of a 2027 annual award.

The company also entered retention agreements with Chevallard, Marc Odrich and Shawn Olsson. Each provides a retention amount equal to 75% of the officer's 2026 target bonus: $180,731, $175,500 and $171,982 respectively. Half is paid in cash in two installments at six and twelve months, and half in performance-vesting restricted stock units.

What this means

A Form 8-K is the report a US public company must file with the Securities and Exchange Commission to disclose material events between its regular quarterly and annual reports. Companies do not write these from scratch; they select numbered items. Item 2.02 covers earnings results, Item 2.05 covers costs tied to exiting or disposing of operations, and Item 5.02 covers the departure or appointment of directors and certain officers. This filing uses all three.

Item 2.05 exists because laying off staff or closing operations costs money that has to be disclosed and later accounted for. The $5 million here is the company's estimate of the one-time bill, mostly severance, and it is expected to land in the fourth quarter of 2026. Because it is an estimate, the filing notes that actual results may differ and that the company would amend the 8-K if it later expects significantly higher costs.

The headcount figure is the core of the story: going from roughly 160 employees to about 40, a 75% reduction. The filing frames the purpose as shifting spending toward consumer marketing while cutting operating expenses, which tells you the company is choosing to fund sales promotion for an existing product rather than broad internal spending.

The CEO change is documented under Item 5.02, the same item used for any board or senior-officer change. The filing is specific that the resignation was not caused by a dispute, a statement companies make precisely because investors otherwise assume a disagreement when a CEO leaves abruptly. The separation agreement is also spelled out in unusual detail – salary continuation, a prorated bonus, forfeiture of unvested equity, no acceleration, and a limited extension of the option exercise window.

An interim CEO appointment means the board has not named a permanent successor. Chevallard holds the CFO role and the top executive role at the same time, and the filing states he will also keep the principal financial and accounting officer designations. His option grant vests in four tranches tied to future start dates, so it only pays out over time and is partly forfeited if he stops serving as interim CEO before those dates.

The next scheduled disclosures are the company's Form 10-K for the year ending December 31, 2026, where the separation and interim CEO agreements are expected to be filed as exhibits, and any amendment to this 8-K if the reorganization costs change materially. Companies are not required to update forward-looking cost estimates simply because circumstances change.